(Informaci\u00f3n remitida por la empresa firmante)<\/p>\n
\nDate & Time: Friday 8 November 2024, 9am \u2013 7pm CDTAbstract Authors: Lian Ni Lee1, Jonathan Kwok1, Anna Maria Theresa Kroon2, Senthil Chinnakannan1, Spyridoula Marinou1, Annemieke Kok1, Callum Beach1, Steve John1, Tim Davies1, Andrew Highton2, Catherine de Lara2, Claire Hutchings2, Robert Parker1, Silvia Salatino2, Orion Tong1, Nicola Ternette2, Uzi Gileadi2, Paul Klenerman2<\/p>\n
\n\u00b9 Infinitopes, Oxford, UK, \u00b2 University of Oxford, Oxford, UK<\/p>\n
\nPoster Title: Precision ImmunomicsTM: Identification of hundreds of novel cancer antigens using a sensitive immunopeptidomics-led platform<\/p>\n
\nAbstract Number: 1427<\/p>\n
\nPrimary Category: Antigen Presentation<\/p>\n
\nPresenting Author: Georges Bedran, Senior Scientist & Computational Immunomics Lead at Infinitopes<\/p>\n
\nDate & Time: Friday 8 November 2024, 9am \u2013 7pm CDT<\/p>\n
\nAbstract Authors: Yuxin Sun\u00b9, Nil Adell Mill\u00b9, Tiffany Ma\u00b9, Yves du Toit\u00b9, Ava Van Ess\u00b9, Chloe Hyun-Jung Lee\u00b9, Spyridoula Marinou\u00b9, Annemieke ten Bokum\u00b9, May Ke\u00b9, Oliver Turnbull\u00b9, Luke Heirene\u00b9, Lian Ni Lee\u00b9, Alexey I. Nesvizhskii\u00b2, Pouya Faridi\u00b3, Paul Klenerman4, Jonathan Kwok\u00b9, Orion Tong\u00b9, Robert Parker\u00b9 and Georges Bedran\u00b9<\/p>\n
\n\u00b9 Infinitopes, Oxford, UK, \u00b2 University of Michigan Medical School, Ann Arbor, USA, \u00b3 Monash University, Melbourne, Australia, 4 University of Oxford, Oxford, UK<\/p>\n
\nAbout Infinitopes<\/p>\n
\nInfinitopes Ltd is a soon to be clinical stage, integrated cancer biotechnology company supported by Cancer Research UK (CRUK) and the University of Oxford. The Company combines two world leading platforms, in precision antigen discovery and in high efficiency, vector delivery systems, to develop immunologically durable vaccines for use against multiple solid tumour indications. The lead vaccine candidate is expected to begin Phase I\/IIa trials in H1′ 25. Infinitopes has gathered together and cultivated in-house talent across antigen discovery, immunology, vaccinology, oncology, biomanufacturing, clinical trials and regulation, winning an ‘Innovative Licensing and Access Pathway’ (ILAP) innovation passport from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in 2022. Infinitopes has also won two prestigious, maximum size nondilutive awards from Innovate UK, a Cancer Therapeutics Award (in 2022) and a Future Economy Investor Partnership (in 2023). Since incorporation, the Infinitopes team has raised nearly $20m from sector expert investors including Cancer Research Horizons, Cancer Research Institute, Kindred Capital, Manta Ray Ventures, Martlet, Meltwind, Octopus Ventures, Saras Capital, Wilbe and the Fundaci\u00f3n CRIS Contra el C\u00e1ncer, funding its rapid growth from three academic co-founders to 28 full time equivalents. It is now the largest tenant of Oxford University’s BioEscalator innovation accelerator. For more information, visit www.infinitopes.com<\/p>\n
\nAbout SITC<\/p>\n
\nSITC 2024 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. The Annual Meeting consists of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for structured and informal discussions, including important networking opportunities. SITC 2024 also includes updates on major national and international initiatives from academia, government and industry, as well as important society projects.<\/p>\n
View original content:https:\/\/www.prnewswire.co.uk\/news-releases\/infinitopes-to-showcase-breakthroughs-on-cancer-vaccine-development-at-sitc-2024-insight-into-a-double-blind-phase-iiia-clinical-trial-302299002.html<\/p>\n","protected":false},"excerpt":{"rendered":"
(Informaci\u00f3n remitida por la empresa firmante) Date & Time: Friday 8 November 2024, 9am \u2013 7pm CDTAbstract Authors: Lian Ni Lee1, Jonathan Kwok1, Anna Maria Theresa Kroon2, Senthil Chinnakannan1, Spyridoula Marinou1, Annemieke Kok1, Callum Beach1, Steve John1, Tim Davies1, Andrew Highton2, Catherine de Lara2, Claire Hutchings2, Robert Parker1, Silvia Salatino2, Orion Tong1, Nicola Ternette2, Uzi […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-56800","post","type-post","status-publish","format-standard","hentry","category-noticias"],"_links":{"self":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/56800","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56800"}],"version-history":[{"count":0,"href":"https:\/\/webciudadana.net\/index.php?rest_route=\/wp\/v2\/posts\/56800\/revisions"}],"wp:attachment":[{"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56800"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56800"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/webciudadana.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56800"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}